{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:38:27Z","timestamp":1747147107019,"version":"3.40.5"},"reference-count":26,"publisher":"Wiley","issue":"22","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Platinum\u2010based chemotherapy remains a first\u2010line standard of care for approximately 30% of patients with non\u2010small cell lung cancer (NSCLC) not harboring a druggable alteration. Favorable efficacy and safety of the <jats:italic>nab<\/jats:italic>\u2010paclitaxel\/carboplatin (<jats:italic>nab<\/jats:italic>\u2010P\/C) combination was shown in the pivotal phase 3 trial. However, information on effectiveness of <jats:italic>nab<\/jats:italic>\u2010P\/C in a real\u2010world setting in Germany is missing. The NEPTUN study prospectively investigated the effectiveness and safety of <jats:italic>nab<\/jats:italic>\u2010P\/C in patients with advanced NSCLC in a real\u2010world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with advanced or metastatic NSCLC received first\u2010line <jats:italic>nab<\/jats:italic>\u2010P\/C according to clinical routine. The primary endpoint was 6\u2010month progression\u2010free survival rate (PFS6). Other endpoints included further effectiveness parameters, safety and quality of life. Data were analyzed descriptively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>408 patients were enrolled. PFS6 was 40.8% (95% confidence interval [CI], 35.3\u201346.2); median PFS was 5.2\u00a0months (95% CI, 4.5\u20135.7). overall response rate was 41.5% (95% CI, 36.3\u201346.8). Median overall survival (OS) was 10.5\u00a0months (95% CI, 9.2\u201311.6). Subgroup analyses revealed median OS for squamous versus non\u2010squamous histology (11.8\u00a0months [95% CI, 9.2\u201313.8] vs. 9.6\u00a0months [95% CI, 7.7\u201311.2]) and age \u226570 versus &lt;70\u00a0years (11.7\u00a0months [95% CI, 9.4\u201314.3] vs. 9.6\u00a0months [95% CI, 7.5\u201311.2]). Most common treatment\u2010emergent adverse events (TEAEs) were anemia (26.5%), leukopenia (25.7%), and thrombocytopenia (16.6%). Mostly reported grade 3\/4 TEAEs were leukopenia (10.2%), anemia (8.6%), and pneumonia (5.1%). <jats:italic>nab<\/jats:italic>\u2010paclitaxel\u2010related deaths as reported by the investigator occurred in 0.8% of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These real\u2010world data support the effectiveness and safety of <jats:italic>nab<\/jats:italic>\u2010P\/C as first\u2010line treatment for patients with advanced NSCLC independent of tumor histology. The results are comparable with the pivotal phase 3 trial. No new safety signals emerged.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.4310","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T12:23:12Z","timestamp":1634818992000},"page":"8127-8137","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["First\u2010line <i>nab<\/i>\u2010paclitaxel plus carboplatin for patients with advanced non\u2010small cell lung cancer: Results of the NEPTUN study"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8976-7328","authenticated-orcid":false,"given":"Tobias","family":"Dechow","sequence":"first","affiliation":[{"name":"Practice for Oncology Ravensburg Ravensburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Riera\u2010Knorrenschild","sequence":"additional","affiliation":[{"name":"University Hospital Giessen and Marburg GmbH Marburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Hackanson","sequence":"additional","affiliation":[{"name":"University Medical Center Augsburg Augsburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Janssen","sequence":"additional","affiliation":[{"name":"Practice for Hematology and Oncology Westerstede Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Schulz","sequence":"additional","affiliation":[{"name":"Practice for Internal Oncology and Hematology Frechen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Chiabudini","sequence":"additional","affiliation":[{"name":"Department of Biostatistics iOMEDICO Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludwig","family":"Fischer von Weikersthal","sequence":"additional","affiliation":[{"name":"Health Center St. Marien GmbH Amberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Budweiser","sequence":"additional","affiliation":[{"name":"Hospital Rosenheim Rosenheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Nacke","sequence":"additional","affiliation":[{"name":"Practice for Hematology and Oncology Remagen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Taeuscher","sequence":"additional","affiliation":[{"name":"SRH Wald\u2010Klinikum Gera GmbH Gera Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Welslau","sequence":"additional","affiliation":[{"name":"Medical Care Center at Hospital Aschaffenburg GmbH Aschaffenburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Potthoff","sequence":"additional","affiliation":[{"name":"Medical Department iOMEDICO Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24223-1_1"},{"key":"e_1_2_10_4_1","unstructured":"EttingerDS WoodDE AisnerDLet al. National Comprehensive Cancer Network NCCN. clinical practice guidelines in oncology (NCCN Guidelines) non\u2010small cell lung cancer. Version 2.2021."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30958-8"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy292.050"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03022"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.6065"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01348"},{"key":"e_1_2_10_16_1","first-page":"207","article-title":"nab\u2010paclitaxel\/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy","volume":"8","author":"Thomas M","year":"2017","journal-title":"Lung Cancer"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14217"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S189556"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.5848"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00253"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00262"},{"key":"e_1_2_10_22_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Accessed June 14 2010.http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13263"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178420"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt235"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy424.077"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.028"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4310","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4310","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T16:56:09Z","timestamp":1693241769000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":26,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1002\/cam4.4310"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4310","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"type":"print","value":"2045-7634"},{"type":"electronic","value":"2045-7634"}],"subject":[],"published":{"date-parts":[[2021,10,20]]},"assertion":[{"value":"2021-07-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}